Riskpilot← Back to searchSign inGet full accessBIOPHARMIA AS
ASActiveOrg 993607479Rundhaugveien 6, 0495 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20090 employeeswww.biopharmia.no
Revenue 2024
NOK 0
EBITDA margin
—
-42% vs 2023
Equity ratio
77.1%
Financial strength
Net profit 2024
NOK -115K
-42% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -115K | -42% |
| Net profit | NOK -115K | -42% |
| Total assets | NOK 10,6M | +0% |
| Equity | NOK 8,1M | -1% |
| Employees | 0 | — |
Legal name
BIOPHARMIA AS
Org number
993607479
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. februar 2009
Share capital
NOK 112 222
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Selskapets formål er å drive bioteknologisk næringsutvikling, rådgivning forbundet hermed, eiendomsutvikling, handel samt hva hermed står i forbindelse, herunder delta i andre selskaper, nasjonalt og internasjonalt.
Address
Rundhaugveien 6, 0495 Oslo
Website
www.biopharmia.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 11 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −22 | −133 | −100 | −81 | −115 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −22 | −133 | −100 | −81 | −115 |
| Net financials | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −22 | −133 | −100 | −81 | −115 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −22 | −133 | −100 | −81 | −115 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 10 567 | 10 557 | 10 568 | 10 575 | 10 564 |
| Equity | 8 575 | 8 442 | 8 341 | 8 260 | 8 146 |
| Long-term debt | 1 955 | 2 073 | 2 181 | 2 311 | 2 418 |
| Short-term debt | 37 | 42 | 46 | 4 | 0 |
| Total debt | 1 992 | 2 115 | 2 226 | 2 315 | 2 418 |
EBITDA margin
-11491900.0%
This company
15.8%
Market median
-72733644% vs market
20202024
Equity ratio
77.1%
This company
38.2%
Market median
+102% vs market
20202024
Return on equity
-1.4%
This company
18.4%
Market median
-108% vs market
20202024
Net profit margin
-11491800.0%
This company
8.1%
Market median
-141874174% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2021 | |
| Former (4) | ||
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 1.36% | 1.36% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOPHARMIA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bertil Gunnar Jörgen Lundberg | Board of Directors | 0 companies |
| Arne Råheim | Board of Directors | 0 companies |
| Roald Audun Flo | Chairman | 0 companies |
| Hamed Saleem Ismail | Board of Directors | 0 companies |
| Mohamed Uzzal Mazumder | Board of Directors | 0 companies |